Literature DB >> 16220476

Bivariate isotonic design for dose-finding with ordered groups.

Anastasia Ivanova1, Kai Wang.   

Abstract

We consider the problem of dose-finding where subjects can be stratified into two populations with possibly different susceptibility to toxicity. The goal is to find the maximally tolerated dose for each population. We propose a non-parametric design for this problem. Toxicity is estimated using the bivariate isotonic regression estimator. The new design is compared with the two-sample continual reassessment method. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16220476     DOI: 10.1002/sim.2312

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  23 in total

1.  Isotonic designs for phase I trials in partially ordered groups.

Authors:  Mark Conaway
Journal:  Clin Trials       Date:  2017-08-04       Impact factor: 2.486

2.  Innovative Clinical Trial Designs: Toward a 21st-Century Health Care System.

Authors:  Tze L Lai; Philip W Lavori
Journal:  Stat Biosci       Date:  2011-12

3.  A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial.

Authors:  Nolan A Wages; Paul W Read; Gina R Petroni
Journal:  Pharm Stat       Date:  2015-05-11       Impact factor: 1.894

4.  Sequential designs for individualized dosing in phase I cancer clinical trials.

Authors:  Xuezhou Mao; Ying Kuen Cheung
Journal:  Contemp Clin Trials       Date:  2016-08-31       Impact factor: 2.226

5.  Adaptive Isotonic Estimation of the Minimum Effective and Peak Doses in the Presence of Covariates.

Authors:  Changfu Xiao; Anastasia Ivanova
Journal:  J Stat Plan Inference       Date:  2012-07-01       Impact factor: 1.111

6.  The Impact of Early-Phase Trial Design in the Drug Development Process.

Authors:  Mark R Conaway; Gina R Petroni
Journal:  Clin Cancer Res       Date:  2018-10-16       Impact factor: 12.531

7.  Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation.

Authors:  Yisheng Li; B Nebiyou Bekele; Yuan Ji; John D Cook
Journal:  Stat Med       Date:  2008-10-30       Impact factor: 2.373

8.  Designs for phase I trials in ordered groups.

Authors:  Mark R Conaway; Nolan A Wages
Journal:  Stat Med       Date:  2016-09-14       Impact factor: 2.373

9.  Risk-group-specific dose finding based on an average toxicity score.

Authors:  B Nebiyou Bekele; Yisheng Li; Yuan Ji
Journal:  Biometrics       Date:  2009-07-23       Impact factor: 2.571

10.  Utility-based optimization of combination therapy using ordinal toxicity and efficacy in phase I/II trials.

Authors:  Nadine Houede; Peter F Thall; Hoang Nguyen; Xavier Paoletti; Andrew Kramar
Journal:  Biometrics       Date:  2009-08-10       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.